Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**GNPs-Dox-Lac** is an experimental, enzyme-responsive and pH-responsive nanomedicine for hepatocellular carcinoma. It consists of gelatin nanoparticles carrying a lactose-conjugated doxorubicin prodrug, doxorubicin-lactose. The approximately 133 nm gelatin carrier is designed to remain stable during circulation and accumulate in tumors; tumor-associated matrix metalloproteinase-2 degrades the gelatin matrix, releasing the smaller doxorubicin-lactose prodrug to improve tumor penetration and cellular uptake. Intracellular acidic conditions then dissociate the prodrug and release free doxorubicin, which intercalates DNA and inhibits topoisomerase II, causing DNA damage and cytotoxicity. In an in vivo hepatocellular carcinoma model, the system produced a reported tumor-inhibition rate of 90.8% with comparatively low toxicity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GNPs-Dox-Lac.